Recent Updates
Recently added Catalysts
GRAL Positive Sentiment

GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings

Saturday, October 18, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: GRAIL, Inc. announced positive results from its PATHFINDER 2 study, showcasing the Galleri multi-cancer early detection blood test. The study revealed a more than seven-fold increase in cancer detection when combined with recommended screenings. Notably, over half of the cancers detected were early-stage, and a significant portion lacked existing screening recommendations.
Price reaction · baseline $78 (2025-10-17 close) · 2 other GRAL headline(s) in the window, move may be shared
day 0 close · peak
+17.8%
day 1
+7.3%
day 3
+6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Galleri test significantly increased cancer detection rates.
  • More than half of detected cancers were in early stages.
  • Three-quarters of cancers identified had no recommended screenings.

Full Press Release Details

More Than Half of Cancers Detected by Galleri Were Early Stage

Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings

PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population

MENLO PARK, Calif.,Oct. 17, 2025/PRNewswire/ -- GRAIL, Inc. (Nasdaq:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251.

Frequently Asked Questions

What is the Galleri test?

The Galleri test is a multi-cancer early detection blood test developed by GRAIL.

What were the results of the PATHFINDER 2 study?

The study showed a more than seven-fold increase in cancer detection rates.

How many cancers detected were early stage?

More than half of the cancers detected by Galleri were classified as early stage.

What percentage of detected cancers lacked recommended screenings?

Approximately three-quarters of the cancers detected did not have recommended screenings.

ShareAdd on Google
Tags: GRAL Viatris Investor Conferences Healthcare GRAIL Galleri cancer detection PATHFINDER 2 early stage cancer
Last updated: Oct 18, 2025

Biotech snapshot

Cash runway
$915M liquidity · $27M/mo burn
~34 mo
Minimal dilution risk